Our Pipeline

Diverse pipeline of innate cell engagers designed to activate innate immunity

A number of clinical and preclinical programs are in development based on the ROCK® platform and our tetravalent bispecific immune cell engagers have already shown a favorable safety profile and promising signs of therapeutic efficacy.

Innate Cell Engagers


Disease Target CD30
Peripheral T cell lymphoma (AFM13-202)
Phase 2
Transformed mycosis fungoides (AFM13-202)
Phase 2
CD30-positive T cell lymphoma (AFM13-102)
Phase 2
HL (post BV and post anti-PD-1) (AFM13-201)
Phase 2

AFM13 + adoptive NK cells

Disease Target CD30
CD30-positive lymphoma (AFM13-104)
Phase 1

AFM13 + anti-PD-1

Disease Target CD30
Hodgkin lymphoma (post BV) (AFM13-103)
Phase 1


Disease Target EGFR
Solid tumors (AFM24-101)
Phase 1

RO7297089 (formerly AFM26)

Disease Target BCMA
Multiple Myeloma
Phase 1

AFM28 and AFM32

Disease Target Undisclosed
Multiple Indications


Disease Target Undisclosed
Multiple Programs
Affimed programs
Partnered programs

Selected posters & publications:

  • Reusch et al., AACR 2020: AFM24, a bispecific EGFR/CD16A Innate Cell Engager with the potential to overcome resistance to current targeted treatments for EGFR-positive malignancies View poster
  • Ellwanger et al., mAbs 2019: Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity. Please see: mAbs 2019; 11:899-918.
  • Sawas et al., 15-ICML 2019: Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202) View poster
  • Oral Presentation: Ansell et al., ICML 2019: Investigating safety and preliminary efficacy of AFM13 plus Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure View poster
  • Bartlett et al., ASH 2018: A Phase 1 Study Investigating the Combination of AFM13 and the Monoclonal Anti-PD-1 Antibody Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data View poster
  • Marin et al., ASH 2018: The CD30/CD16A Bispecific Innate Immune Cell Engager AFM13 Elicits Heterogeneous Single-cell NK Cell Responses and Effectively Triggers Memory Like (ML) NK Cells View poster
  • Wingert et al., ASH 2018: CD16A-Specific Tetravalent Bispecific Immuno-Engagers Potently Induce Antibody-Dependent Cellular Phagocytosis (ADCP) by Macrophages View poster
  • Kluge et al., AACR 2018: Preclinical Characterization of the Bispecific EGFR/CD16A Innate Immune Cell Engager AFM24 for the Treatment of EGFR-Expressing Solid Tumors View poster

See all Publications & Posters